Moderate evidence
More
Blood test using portable light scanner tested on 280 people to sort ovarian tumors
Study title: Rapid serum-based differentiation of ovarian tumors and assessment of post-treatment disease-free status using portable Raman spectroscopy and machine learning
- Evidence type
- Controlled or validated comparison
- Sample
- n = 280
- Sources
- 1 sourcePeer-reviewed
- Published
- 1 min read
- Truvace record
- TRV-2026-1189cite or check it
Study title: Rapid serum-based differentiation of ovarian tumors and assessment of post-treatment disease-free status using portable Raman spectroscopy and machine learning
Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity. Serum contains proteins, lipids, carbohydrates, and nucleic acids that generate disease-related spectrochemical fingerprints, which portable Raman spectroscopy can capture with minimal sample preparation.
Read the study abstract
Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity. Serum contains proteins, lipids, carbohydrates, and nucleic acids that generate disease-related spectrochemical fingerprints, which portable Raman spectroscopy can capture with minimal sample preparation. We investigated serum Raman profiling for ovarian tumor discrimination and cross-sectional characterization of post…

The gain
Portable Raman spectroscopy with machine learning offers a rapid, low-cost serum approach to distinguish ovarian tumors and assess post-treatment status, where CA125 is limited.
In brief
We investigated serum Raman profiling for ovarian tumor discrimination and cross-sectional characterization of post-treatment disease-free status. Serum samples from 280 participants (85 benign, 82 malignant, and 113 independent follow-up patients) were analyzed over 400-1800 cm⁻ 1 .
Main points
- Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity.
- Serum contains proteins, lipids, carbohydrates, and nucleic acids that generate disease-related spectrochemical fingerprints, which portable Raman spectroscopy can capture with minimal sample preparation.
- We investigated serum Raman profiling for ovarian tumor discrimination and cross-sectional characterization of post-treatment disease-free status.
The full story
Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity. Serum contains proteins, lipids, carbohydrates, and nucleic acids that generate disease-related spectrochemical fingerprints, which portable Raman spectroscopy can capture with minimal sample preparation.
Sources
1 on file- Analytical and Bioanalytical Chemistrydoi:10.1007/s00216-026-06823-5
ace
What readers say